Disease-Specific Template: Difference between revisions - Compendium of Cancer Genome Aberrations

(2 intermediate revisions by 2 users not shown)

Line 1:

''(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ HUGO-approved gene names and symbols] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author Instructions]] and [[Frequently Asked Questions (FAQs)|FAQs]] as well as contact your [[Leadership|Associate Editor]] or [[Mailto:CCGA@cancergenomics.org|Technical Support]].)''

==Primary Author(s)*==

Put your text here ~~(''Name and affiliation; example:'' Jane Smith, PhD, Institute of Genomics)~~

Put your text here

__TOC__

Line 16:

Line 15:

==Definition / Description of Disease==

Put your text here (''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories referring to the specific WHO book pages, diagnostic criteria if applicable, and differential diagnosis if applicable'')

Put your text here

==Synonyms / Terminology==

Put your text here ~~(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'')~~

Put your text here

==Epidemiology / Prevalence==

Line 28:

Line 27:

==Clinical Features==

Put your text here and fill in the table ~~(''Instruction: Can include references in the table'')~~

Put your text here and fill in the table

{| class="wikitable"

|'''Signs and Symptoms'''

Line 47:

Line 46:

==Sites of Involvement==

Put your text here ~~(''Instruction: Indicate physical sites; Example: nodal, extranodal, bone marrow'')~~

Put your text here

==Morphologic Features==

Line 55:

Line 54:

==Immunophenotype==

Put your text here and fill in the table ~~(''Instruction: Can include references in the table'')~~

Put your text here and fill in the table

{| class="wikitable sortable"

Line 94:

Line 93:

==Individual Region Genomic Gain/Loss/LOH==

Put your text here and fill in the table ~~(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'')~~

Put your text here and fill in the table

{| class="wikitable sortable"

Line 140:

Line 139:

==Characteristic Chromosomal Patterns==

Put your text here ''(EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis)''

Put your text here

{| class="wikitable sortable"

Line 162:

Line 161:

==Gene Mutations (SNV/INDEL)==

Put your text here and fill in the table (''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.)''

Put your text here and fill in the table

{| class="wikitable sortable"

Line 199:

Line 198:

==Genes and Main Pathways Involved==

Put your text here and fill in the table ~~''(Instructions: Can include references in the table.)''~~

Put your text here and fill in the table

{| class="wikitable sortable"

|-

Line 222:

Line 221:

==Familial Forms==

Put your text here ~~(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'')~~

Put your text here

==Additional Information==

Line 230:

Line 229:

==Links==

Put your text placeholder here (use "Link" icon at top of page~~) (''Instructions: For example, link to related gene pages within the site. Note: links will be converted using the link icon at top of page in the CCGA site.''~~)

Put your text placeholder here (use "Link" icon at top of page)

==References==

(use "Cite" icon at top of page)

(''~~Instruction: Add PMIDs into the text above where references are appropriate - PMIDs will be used to insert references on the CCGA site and the reference list automatically generated'')~~

'''EXAMPLE Book'''

(''~~Instruction: If a PMID is not available, such as for a book, please include the entire reference in this section~~''~~)<references />~~

~~===EXAMPLE Book===~~

#Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.

@@ Line 1: / Line 1: @@
-''(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ HUGO-approved gene names and symbols] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author Instructions]] and [[Frequently Asked Questions (FAQs)|FAQs]] as well as contact your [[Leadership|Associate Editor]] or [[Mailto:CCGA@cancergenomics.org|Technical Support]].)''
 ==Primary Author(s)*==
-Put your text here (''Name and affiliation; example:'' Jane Smith, PhD, Institute of Genomics)
+Put your text here
 __TOC__
@@ Line 16: / Line 15: @@
 ==Definition / Description of Disease==
-Put your text here (''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories referring to the specific WHO book pages, diagnostic criteria if applicable, and differential diagnosis if applicable'')
+Put your text here
 ==Synonyms / Terminology==
-Put your text here (''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'')
+Put your text here
 ==Epidemiology / Prevalence==
@@ Line 28: / Line 27: @@
 ==Clinical Features==
-Put your text here and fill in the table (''Instruction: Can include references in the table'')
+Put your text here and fill in the table
 {| class="wikitable"
 |'''Signs and Symptoms'''
@@ Line 47: / Line 46: @@
 ==Sites of Involvement==
-Put your text here (''Instruction: Indicate physical sites; Example: nodal, extranodal, bone marrow'')
+Put your text here
 ==Morphologic Features==
@@ Line 55: / Line 54: @@
 ==Immunophenotype==
-Put your text here and fill in the table (''Instruction: Can include references in the table'')
+Put your text here and fill in the table
 {| class="wikitable sortable"
@@ Line 94: / Line 93: @@
 ==Individual Region Genomic Gain/Loss/LOH==
-Put your text here and fill in the table (''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'')
+Put your text here and fill in the table
 {| class="wikitable sortable"
@@ Line 140: / Line 139: @@
 ==Characteristic Chromosomal Patterns==
-Put your text here ''(EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis)''
+Put your text here
 {| class="wikitable sortable"
@@ Line 162: / Line 161: @@
 ==Gene Mutations (SNV/INDEL)==
-Put your text here and fill in the table (''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.)''
+Put your text here and fill in the table
 {| class="wikitable sortable"
@@ Line 199: / Line 198: @@
 ==Genes and Main Pathways Involved==
-Put your text here and fill in the table ''(Instructions: Can include references in the table.)''
+Put your text here and fill in the table
 {| class="wikitable sortable"
 |-
@@ Line 222: / Line 221: @@
 ==Familial Forms==
-Put your text here (''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'')
+Put your text here
 ==Additional Information==
@@ Line 230: / Line 229: @@
 ==Links==
-Put your text placeholder here (use "Link" icon at top of page) (''Instructions: For example, link to related gene pages within the site. Note: links will be converted using the link icon at top of page in the CCGA site.'')
+Put your text placeholder here (use "Link" icon at top of page)
 ==References==
+<references />
 (use "Cite" icon at top of page)
-(''Instruction: Add PMIDs into the text above where references are appropriate - PMIDs will be used to insert references on the CCGA site and the reference list automatically generated'')
+'''EXAMPLE Book'''
-(''Instruction: If a PMID is not available, such as for a book, please include the entire reference in this section'')<references />
-===EXAMPLE Book===
 #Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.